Immune responses to gene-modified, autologous dendritic cell vaccines in melanoma

黑色素瘤中基因修饰的自体树突状细胞疫苗的免疫反应

基本信息

批准号：
7244117
负责人：
James William Young
金额：
$ 31.47万
依托单位：
SLOAN-KETTERING INST CAN RESEARCH
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-07-01 至 2012-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7244117
关键词：
Alleles Antigen Presentation Antigens Autoantigens Autologous Autologous Dendritic Cells Biological Assay CD34 gene Cell Cycle Cell surface Cells Cessation of life Class Clinical Clinical Trials Coupling Cytomegalovirus Data Dendritic Cell Vaccine Dendritic Cells Dermal Epitopes Evaluation Flow Cytometry Flu matrix protein Gene-Modified Genes Genetic Goals HLA A*0201 antigen Hematopoietic stem cells Human Immune Immune Tolerance Immune response Immunity Immunization Immunologic Monitoring Influenza Keyhole Limpet Hemocyanin Langerhans cell Length MHC Class I Genes MHC Class II Genes Malignant Neoplasms Modeling Modification Monitor Monophenol Monooxygenase Mutation Outcome Patients Peptide/MHC Complex Peptides Phase I Clinical Trials Physiologic pulse Population Process Pulse taking Relative (related person)Retroviral Vector Risk Safety Solutions Staging Standards of Weights and Measures T-Lymphocyte Testing Therapeutic Time Toxic effect Transgenes Tumor Antigens Vaccines Viral Antigens Zalcitabine base cancer cell comparative cytokine flu immunogenic improved in vivo interest interstitial melanoma monocyte pre-clinical progenitor response retroviral transduction tumor tyrosinase peptide

项目摘要

DESCRIPTION (provided by applicant): Advances in our understanding of human dendritic cells have resolved many important unknowns about the onset of immunity and how dendritic cells could control these responses against cancer. Tumor antigens are poor immunogens by themselves, because they are either self or altered-self antigens. Hence the bar to overcoming tolerance toward cancer-self antigens, while attainable, is quite high. Dendritic cells can circumvent many of these barriers by presenting tumor antigens in association with all the other requisite molecules that elicit immune reactivity. Genetic strategies offer potential advantages in coupling tumor antigens to dendritic cells. Compared with standard peptide-pulsing, multiple epitopes can be expressed by genetically modified dendritic cells, which can be processed and tailored to a variety of MHC alleles. Sustained antigen-presentation is more likely and can be monitored over time. We have generated substantial preclinical data using common viral antigens (influenza, CMV) as models, in lieu of tumor antigens. We have successfully transduced CD34+ progenitors, however, that differentiate into Langerhans- type dendritic cells and express full-length human tyrosinase, an important melanoma antigen. We now propose a human clinical trial in patients with advanced melanoma (stages III-IV). We will compare Langerhans-type dendritic cells genetically modified by retroviral transduction to express full-length human tyrosinase with Langerhans cells pulsed with the HLA-A*0201 -restricted tyrosinase peptide. Safety and toxicity will be assessed in this phase I trial. Additional response assessments include detailed immune monitoring by ELISpot. tetramer reactivity, and flow cytometry-based cytokine secretion assays, comparing post-vaccine responses with pre-treatment baselines. These studies will provide proof of principle for any advantage to sustained presentation of multiple class I and II MHC epitopes over presentation of a single class I MHC peptide to stimulate adaptive tumor-specific immunity. (LAY SUMMARY: Genetic alterations of specialized Langerhans-type dendritic cells will be tested for safety, toxicity, and the stimulation of tumor- specific immunity in patients with advanced stage III-IV melanoma.)

描述（由申请人提供）：我们对人类树突细胞的理解的进步已经解决了许多有关免疫发作以及树突状细胞如何控制这些针对癌症的反应的重要未知。肿瘤抗原本身是不良的免疫原子，因为它们是自我或改变自身的抗原。因此，可以克服对癌症抗原的耐受性的标准虽然可以实现，却很高。树突状细胞可以通过与所有其他引起免疫反应性的其他必要分子相关的肿瘤抗原来规避这些障碍。遗传策略在将肿瘤抗原与树突状细胞耦合方面具有潜在的优势。与标准肽脉冲相比，可以通过转基因的树突状细胞来表达多个表位，可以对其进行加工和量身定制。持续的抗原表现更有可能，并且可以随着时间的流逝而受到监测。我们已经使用常见病毒抗原（流感，CMV）作为模型生成了大量的临床前数据，以代替肿瘤抗原。但是，我们成功地转导了CD34+祖细胞，这些祖细胞分化为Langerhans-型树突状细胞，并表达全长的人酪氨酸酶（一种重要的黑色素瘤抗原）。现在，我们提出了晚期黑色素瘤患者（III-IV阶段）的人类临床试验。我们将比较langerhans-type树突状细胞通过逆转录病毒转导遗传修饰，以用HLA-A*0201限制性酪氨酸酶肽脉冲的兰格汉细胞表达全长的人酪氨酸酶。安全性和毒性将在此I阶段试验中进行评估。其他响应评估包括ELISPOT的详细免疫监测。四聚体反应性和基于流式细胞仪的细胞因子分泌测定，将疫接种后反应与治疗前基线进行比较。这些研究将提供原理证明，以持续表现出多个I类和II类MHC表位以呈现单个I类MHC肽以刺激适应性肿瘤特异性免疫的表现。（摘要：在晚期IIII-IV期黑色素瘤患者中，将测试专门的Langerhans型树突状细胞的遗传改变，以确保安全性，毒性和刺激肿瘤特异性免疫。